Investors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the ...

Fintel reports that on September 27, 2024, Cantor Fitzgerald initiated coverage of Amgen (NasdaqGS:AMGN) with a Overweight ...

On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...

Hippocratic AI is developing a generative AI model that aims to help providers complete non-diagnostic and patient-facing tasks ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Shares of Amgen Inc. AMGN advanced 1.99% to $319.10 Thursday, on what proved to be an all-around great trading session for ...

In a sealed order that issued on September 24, 2024, the District Court for the Northern District of West Virginia denied a preliminary ...

How would I invest a chunk of money today? I’d load up on dividend magnet stocks, sit back and watch Fed Chair Jay Powell ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

RBC Capital analyst Gregory Renza maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $362.00. The ...

Overdiagnosis occurs when patients are diagnosed with a disease that would otherwise never have affected the quality or duration of their lives. This often happens unintentionally through well-meaning ...

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...